Bank of Nova Scotia
APLS

Bank of Nova Scotia’s Apellis Pharmaceuticals APLS Stock Holding History

Bank of Nova Scotia’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,070,141
Closed -$26.9M – 1083
2025
Q4 		$26.9M Sell
1,070,141
-386,084
-27% -$9.06M 0.04% 292
2025
Q3 		$33M Buy
1,456,225
+861,413
+145% +$20.1M 0.06% 223
2025
Q2 		$10.3M Buy
+594,812
New +$11M 0.02% 384
2024
Q1 		– Sell
-6,443
Closed -$386K – 1000
2023
Q4 		$386K Sell
6,443
-286,862
-98% -$14.6M ﹤0.01% 905
2023
Q3 		$11.2M Buy
293,305
+288,685
+6,249% +$12.7M 0.03% 303
2023
Q2 		$421K Buy
+4,620
New +$399K ﹤0.01% 856

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bank of Nova Scotia's APLS Position: Q1 2026 in Review

Bank of Nova Scotia sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 1,070,141 shares — an estimated $26.9M sold.

Bank of Nova Scotia first reported a position in APLS in Q2 2023 and held it in 6 quarters. The position peaked at $33M in Q3 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Bank of Nova Scotia reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 1,070,141 Apellis Pharmaceuticals shares in Q1 2026, an estimated $26.9M.
  • Bank of Nova Scotia first reported a position in Apellis Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Bank of Nova Scotia's Apellis Pharmaceuticals position peaked at $33M in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.